Posted by News Agencies July 30, 2024

” src=”https://s.yimg.com/ny/api/res/1.2/L_g_9y.1A8uiqxhoBuHTPA–/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU5OQ–/https://media.zenfs.com/en/investopedia_245/8f581f6b87f0a925f8cb914ee6a85c2b” data-src=”https://s.yimg.com/ny/api/res/1.2/L_g_9y.1A8uiqxhoBuHTPA–/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU5OQ–/https://media.zenfs.com/en/investopedia_245/8f581f6b87f0a925f8cb914ee6a85c2b”>

Key Takeaways

• Merck & Co. reduced its full-year adjusted EPS projection to between $7.94 and $8.04 from its prior guidance of $8.53 to $8.65.

• Second-quarter sales of its flagship drug Keytruda rose 16% year-over-year.

• The company beat Q2 expectations on the top and bottom lines.

Shares of Merck & Co. (MRK) tumbled Tuesday after the pharmaceutical giant cut its full-year adjusted profit guidance.

The producer of the cancer drug Keytruda now expects full-year adjusted earnings per share (EPS) of between $7.94 and $8.04, down from its prior guidance of $8.53 to $8.65. The change reflects the impact from a one-time charge of about $1.3 billion, or $0.51 per share, for the acquisition of EyeBio.

Merck Beats Q2 Revenue, Profit Estimates

In the second quarter, Merck posted EPS of $2.14 on revenue of $16.11 billion, topping analysts’ expectations of $2.05 and $15.88 billion, per Visible Alpha.

The company’s pharmaceutical arm delivered $14.41 billion in revenue, up 7% from a year ago, led by its flagship cancer drug Keytruda, which saw sales rise 16% to $7.27 billion. Winrevair, a pulmonary arterial hypertension drug approved by the Food and Drug Administration (FDA) in March, saw sales of $70 million.

Shares of Merck sank more than 9% to $115.91 as of 11:30 a.m. ET Tuesday. 

Read the original article on Investopedia.

EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel